Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects

NCT01069367 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Swine-Origin Influenza A H1N1 Virus

Interventions

BIOLOGICAL: Emulsion, Cell Culture-based, influenza HA vaccine H1N1

Sponsor

Novartis Vaccines